Products for Research Use Only

ACHRE / CHRNE Peptide

CAT: 0013-GTR18915783Size: 0.1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR18915783Size:0.1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ACHRE / CHRNE Peptide
Product Name Alternative
CHRNE, cholinergic receptor, nicotinic, epsilon, ACHRE, CMS1D, CMS1E, CMS2A, FCCMS, SCCMS, AchR epsilon subunit, cholinergic receptor, nicotinic, epsilon polypeptide, nicotinic acetylcholine receptor epsilon polypeptide
UniProt
Q04844
Field of Research
Neuroscience
Form
Lyophilized
Storage Conditions
Store at -20°C. When reconstituted minimize freezing and thawing.
Notes
For research use only.
Applications Notes
ACHRE / CHRNE peptide is used for blocking the activity of ACHRE / CHRNE antibody. Mix equal volume of peptide and antibody at the required dilution and leave at ambient temperature for 20 minutes. Then incubate and develop in parallel two blots: one with the antibody and one with the antibody which has been pre-absorbed with the provided peptide.
Tested Applications
Blocking
NCBI Accession Number
NP_000071.1
Preservative
ACHRE / CHRNE peptide is supplied as 100 μg of dried peptide. When the peptide is reconstituted in 200 μL water, the concentration will be 0.5 mg/mL.

UniProtKB · Q04844

Acetylcholine receptor subunit epsilon

ACHE_HUMAN · Homo sapiens

View on UniProt ↗
Primary accession
Q04844
Review status
UniProtKB reviewed (Swiss-Prot)
Gene
CHRNE
Protein existence
1: Evidence at protein level
Organism
Homo sapiens (Human)
Taxonomy ID
9606
Alternative names
—
EC number
—
Processing
Precursor
Secondary accessions
D3DTK6
Protein keywords

Technical term

3D-structureReference proteome

Cellular component

Cell membraneMembranePostsynaptic cell membraneSynapse

Disease

Congenital myasthenic syndromeDisease variant

PTM

Disulfide bondGlycoprotein

Molecular function

Ion channelLigand-gated ion channelReceptor

Biological process

Ion transportTransport

Domain

SignalTransmembraneTransmembrane helix